Abstract:INTRODUCTION AND OBJECTIVES: Docetaxel (DTX) is one of the primary drugs used for treating castration resistant prostate cancer (CRPC).Unfortunately, over time patients invariably develop resistance to DTX therapy and their disease will continue to progress.The mechanisms by which resistance develops is still incompletely understood.This study seeks to determine the involvement of miRNAs, specifically miR-181a, in DTX resistance in CRPC.METHODS: Total RNA from parental C4-2B prostate cancer cells and DTX resistant C4-2B cells (C4-2B TaxR) was submitted for small RNA deep sequencing.Data was analyzed to ascertain which miRNAs expressions were most altered in C4-2B TaxR cells compared to parental cells.Having identified an increase in miR-181a in resistant cells, its expression was modulated in C4-2B and C4-2B TaxR cells by transfecting them with miR-181a mimics or antisense, respectively.Following transfection, cell number was determined after 48 h with or without DTX.Cross resistance to cabazitaxel induced by miR-181a was also determined.Western blots were used to determine ABCB1 protein expression and rhodamine assays used to assess activity.Phospho-p53 expression was assessed by western blot and apoptosis was measured by ELISA in C4-2B TaxR cells with inhibited miR-181a expression with or without DTX.RESULTS: miR-181a is significantly upregulated in C4-2B TaxR cells compared to parental C4-2B cells as analyzed by small RNA sequencing.Overexpression of miR-181a in C4-2B cells confers DTX and cabazitaxel resistance.Knockdown of miR-181a in C4-2B TaxR cells re-sensitizes them to treatment with both DTX and cabazitaxel.miR-181a knockdown alone induced apoptosis in C4-2B TaxR cells which is further enhanced by DTX.We next assessed if miR-181a altered expression or activity of ABCB1, which is overexpressed/active in C4-2B TaxR cells and promotes resistance to DTX by pumping the drug out of cells.We found that miR-181a does not impact ABCB1 expression or activity.Since we previously demonstrated that phospho-p53 can modulate DTX sensitivity, we determined if miR-181a can alter p53 expression in C4-2B TaxR cells.Knockdown of miR-181a in C4-2B TaxR cells induced phospho-p53 expression, suggesting that miR-181a induced resistance to DTX is mediated by inhibition of phospho-p53 expression.CONCLUSIONS: Overexpression of mir-181a in C4-2B TaxR cells contributes to their resistance to DTX and inhibition of mir-181a expression can restore treatment response.This is due, in part, to modulation of p53 phosphorylation and induction of apoptosis.

Txr1: A Transcriptional Regulator Of Thrombospondin-1 That Modulates Cellular Sensitivity To Taxanes

Targeting XPO6 Inhibits Prostate Cancer Progression and Enhances the Suppressive Efficacy of Docetaxel

Reversal of Taxol Resistance by Cisplatin in Nasopharyngeal Carcinoma by Upregulating Thromspondin-1 Expression

Therapeutic Targeting of MDR1 Expression by RORγ Antagonists Resensitizes Cross-Resistant CRPC to Taxane Via Coordinated Induction of Cell Death Programs.

Androgen receptor transcriptional activity and chromatin modifications on the ABCB1/MDR gene are critical for taxol resistance in ovarian cancer cells

Preparation of Antibodies Against TXR1 and Construction of a New DNA Tumor Vaccine.

Secreted Frizzled Related Protein 1 Modulates Taxane Resistance of Human Lung Adenocarcinoma.

Establishment and Characterization of a Docetaxel-Resistant Human Prostate Cancer Cell Line.

Role of Tumor Necrosis Factor Alpha-Induced Protein 1 in Paclitaxel Resistance.

TCRP1 Induces Tamoxifen Resistance by Promoting the Activation of SGK1 in MCF‑7 Cells.

Thioredoxin interacting protein (TXNIP) acts as a tumor suppressor in human prostate cancer

A comprehensive gene expression profile analysis of prostate cancer cells resistant to paclitaxel and the potent target to reverse resistance

Inhibition Of The Androgen Receptor As A Novel Mechanism Of Taxol Chemotherapy In Prostate Cancer

Thioredoxin 1 Upregulates FOXO1 Transcriptional Activity in Drug Resistance in Ovarian Cancer Cells.

Abstract 4378: Identification of novel TXNIP-dependent antitumor pathways in breast cancer

Abstract P2-16-02: TXNIP-dependent tumor suppressive pathways in breast cancer growth and progression

Targeting the Androgen Receptor by Taxol in Castration-Resistant Prostate Cancer.

TPX2 Enhances the Transcription Factor Activation of PXR and Enhances the Resistance of Hepatocellular Carcinoma Cells to Antitumor Drugs

Single-Cell Transcriptomics Analysis Identifies Nuclear Protein 1 As a Regulator of Docetaxel Resistance in Prostate Cancer Cells

Androgen Receptor Splice Variants Circumvent Ar Blockade By Microtubule-Targeting Agents

MP99-17 CIRCULARRNA-C17 ALTERS THE ANTI ANDROGEN-ENZALUTAMIDE RESISTANCE IN CASTRATION-RESISTANT PROSTATE CANCER VIA REGULATING ANDROGEN RECEPTOR VARIANT ARV7 EXPRESSION